SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: May 6, 2003
QLT Inc.
------------------------------------------------------
(Exact name of registrant as specified in its Charter)
British Columbia, Canada 000-17082 N/A
- ------------------------ ------------------------ -------------------
(Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
QLT Inc.,
887 Great Northern Way,
Vancouver, B.C., CANADA, V5T 4T5
(604) 707-7000
-------------------------------------------------------------------------
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
ITEM 5. OTHER EVENTS
On May 6, 2003, QLT Inc. announced that new data presented at the
Association for Research in Vision and Ophthalmology annual meeting
suggest that Visudyne therapy reduces the risk of vision loss in
"wet" age-related macular degeneration (AMD) patients with minimally
classic lesions, a form of wet AMD previously considered
untreatable. Additional data to support the role of Visudyne in
patients with predominantly classic AMD demonstrate that visual
outcomes continue to remain stable five years after initiating
therapy, providing further evidence of the safety and long-term
efficacy of Visudyne.
ITEM 7. EXHIBITS
Exhibit
Number Description
- ------ -----------
99.1 Press release dated May 6, 2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
QLT Inc.
-------------------------------------
(Registrant)
Date May 6, 2003 /s/ Paul J. Hastings
------------------------------ -------------------------------------
(Signature)
President and Chief Executive Officer